Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma

Abstract Background Lung adenocarcinoma (LUAD) is the most common lung cancer worldwide. N6‐methyladenosine (m6A) methylation is a messenger RNA (mRNA) modification that plays a key role in tumor growth, immune microenvironment, and immunotherapy response. This study investigated the expression leve...

Full description

Bibliographic Details
Main Authors: Lei Guo, Qilin Huai, Bolun Zhou, Jianming Ying, Wei Guo
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Cancer Innovation
Subjects:
Online Access:https://doi.org/10.1002/cai2.40
_version_ 1811293097806528512
author Lei Guo
Qilin Huai
Bolun Zhou
Jianming Ying
Wei Guo
author_facet Lei Guo
Qilin Huai
Bolun Zhou
Jianming Ying
Wei Guo
author_sort Lei Guo
collection DOAJ
description Abstract Background Lung adenocarcinoma (LUAD) is the most common lung cancer worldwide. N6‐methyladenosine (m6A) methylation is a messenger RNA (mRNA) modification that plays a key role in tumor growth, immune microenvironment, and immunotherapy response. This study investigated the expression level, mutation status, prognostic value, and predictive ability for response to anti‐PD‐1 immunotherapy of the m6A methyltransferase KIAA1429 in LUAD. Methods This study examined multiple public data cohorts and independent samples from National Cancer Center (NCC) to evaluate the clinical significance and prognostic value of KIAA1429 in LUAD using bioinformatics techniques and immunohistochemical staining. We also evaluated the predictive value of KIAA1429 expression for anti‐PD‐1 immunotherapy efficacy. GSEA analysis was performed using KIAA1429 RNA‐seq data at the tumor tissue level and cellular level to explore the potential molecular mechanism. Results In public databases, KIAA1429 was significantly associated with clinicopathological parameters in LUAD patients and had the potential to predict patient prognosis. The mutation characteristics of KIAA1429‐related genes were analyzed and TP53, TTN, CSMD3, and other genes showed high mutation frequencies in LUAD. An independent cohort of 415 samples confirmed that high KIAA1429 expression was significantly associated with poorer prognosis in LUAD patients. Analysis of a small immunotherapy cohort showed that patients with high expression of KIAA1429 had better response after immunotherapy, and the proportion of patients with immunotherapy response was higher in this group. Conclusions Our study confirmed that KIAA1429 was highly expressed in LUAD and was significantly associated with poor prognosis. Moreover, KIAA1429 may serve as a potential marker to predict the efficacy of immunotherapy in LUAD.
first_indexed 2024-04-13T04:56:24Z
format Article
id doaj.art-a6cb3e340af44ade84027f634e8e2c76
institution Directory Open Access Journal
issn 2770-9183
language English
last_indexed 2024-04-13T04:56:24Z
publishDate 2022-12-01
publisher Wiley
record_format Article
series Cancer Innovation
spelling doaj.art-a6cb3e340af44ade84027f634e8e2c762022-12-22T03:01:28ZengWileyCancer Innovation2770-91832022-12-011432834310.1002/cai2.40Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinomaLei Guo0Qilin Huai1Bolun Zhou2Jianming Ying3Wei Guo4Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing The People's Republic of ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing The People's Republic of ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing The People's Republic of ChinaDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing The People's Republic of ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing The People's Republic of ChinaAbstract Background Lung adenocarcinoma (LUAD) is the most common lung cancer worldwide. N6‐methyladenosine (m6A) methylation is a messenger RNA (mRNA) modification that plays a key role in tumor growth, immune microenvironment, and immunotherapy response. This study investigated the expression level, mutation status, prognostic value, and predictive ability for response to anti‐PD‐1 immunotherapy of the m6A methyltransferase KIAA1429 in LUAD. Methods This study examined multiple public data cohorts and independent samples from National Cancer Center (NCC) to evaluate the clinical significance and prognostic value of KIAA1429 in LUAD using bioinformatics techniques and immunohistochemical staining. We also evaluated the predictive value of KIAA1429 expression for anti‐PD‐1 immunotherapy efficacy. GSEA analysis was performed using KIAA1429 RNA‐seq data at the tumor tissue level and cellular level to explore the potential molecular mechanism. Results In public databases, KIAA1429 was significantly associated with clinicopathological parameters in LUAD patients and had the potential to predict patient prognosis. The mutation characteristics of KIAA1429‐related genes were analyzed and TP53, TTN, CSMD3, and other genes showed high mutation frequencies in LUAD. An independent cohort of 415 samples confirmed that high KIAA1429 expression was significantly associated with poorer prognosis in LUAD patients. Analysis of a small immunotherapy cohort showed that patients with high expression of KIAA1429 had better response after immunotherapy, and the proportion of patients with immunotherapy response was higher in this group. Conclusions Our study confirmed that KIAA1429 was highly expressed in LUAD and was significantly associated with poor prognosis. Moreover, KIAA1429 may serve as a potential marker to predict the efficacy of immunotherapy in LUAD.https://doi.org/10.1002/cai2.40KIAA1429lung adenocarcinomam6A methylationimmunotherapyprognosis
spellingShingle Lei Guo
Qilin Huai
Bolun Zhou
Jianming Ying
Wei Guo
Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
Cancer Innovation
KIAA1429
lung adenocarcinoma
m6A methylation
immunotherapy
prognosis
title Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
title_full Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
title_fullStr Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
title_full_unstemmed Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
title_short Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
title_sort comprehensive analysis of the prognostic impact and immune implication of kiaa1429 in lung adenocarcinoma
topic KIAA1429
lung adenocarcinoma
m6A methylation
immunotherapy
prognosis
url https://doi.org/10.1002/cai2.40
work_keys_str_mv AT leiguo comprehensiveanalysisoftheprognosticimpactandimmuneimplicationofkiaa1429inlungadenocarcinoma
AT qilinhuai comprehensiveanalysisoftheprognosticimpactandimmuneimplicationofkiaa1429inlungadenocarcinoma
AT bolunzhou comprehensiveanalysisoftheprognosticimpactandimmuneimplicationofkiaa1429inlungadenocarcinoma
AT jianmingying comprehensiveanalysisoftheprognosticimpactandimmuneimplicationofkiaa1429inlungadenocarcinoma
AT weiguo comprehensiveanalysisoftheprognosticimpactandimmuneimplicationofkiaa1429inlungadenocarcinoma